AR122020A1 - Sistemas y métodos para la conjugación específica de sitio de proteínas mediada por tirosinasa - Google Patents
Sistemas y métodos para la conjugación específica de sitio de proteínas mediada por tirosinasaInfo
- Publication number
- AR122020A1 AR122020A1 ARP210101231A ARP210101231A AR122020A1 AR 122020 A1 AR122020 A1 AR 122020A1 AR P210101231 A ARP210101231 A AR P210101231A AR P210101231 A ARP210101231 A AR P210101231A AR 122020 A1 AR122020 A1 AR 122020A1
- Authority
- AR
- Argentina
- Prior art keywords
- tco
- functionalized
- tyrosinase
- quinone
- ortho
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020405P | 2020-05-05 | 2020-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122020A1 true AR122020A1 (es) | 2022-08-03 |
Family
ID=76160021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101231A AR122020A1 (es) | 2020-05-05 | 2021-05-05 | Sistemas y métodos para la conjugación específica de sitio de proteínas mediada por tirosinasa |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230192760A1 (https=) |
| EP (1) | EP4146665A1 (https=) |
| JP (1) | JP2023524288A (https=) |
| CN (1) | CN115551875A (https=) |
| AR (1) | AR122020A1 (https=) |
| TW (1) | TW202207988A (https=) |
| WO (1) | WO2021226247A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119731192A (zh) * | 2022-10-14 | 2025-03-28 | 香港中文大学 | 免疫球蛋白的位点特异性酪氨酸修饰 |
| EP4653020A1 (en) * | 2023-01-19 | 2025-11-26 | Shanghai Shengdi Pharmaceutical Co., Ltd | Tyrosinase-mediated protein site-specific conjugation and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| CN101048506B (zh) | 2004-10-27 | 2013-06-26 | 斯克利普斯研究院 | 体内掺入非天然氨基酸的正交翻译组分 |
| AU2007224019A1 (en) | 2006-03-03 | 2007-09-13 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
| EP2222341B1 (en) * | 2007-11-21 | 2015-02-25 | University Of Georgia Research Foundation, Inc. | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds |
| EP2882868B1 (en) * | 2012-08-08 | 2019-07-31 | H. Hoffnabb-La Roche Ag | Increasing dynamic range for identifying multiple epitopes in cells |
| EP2974744A1 (en) * | 2014-07-16 | 2016-01-20 | Stichting Katholieke Universiteit | Strain-promoted oxidation controlled cycloaddition with high reaction rate |
| EP3424538A1 (en) * | 2017-07-06 | 2019-01-09 | Centre National De La Recherche Scientifique | Bioconjugates with a controlled degree of conjugation, their process of preparation, and the reagents for their preparation |
| CA3099421C (en) * | 2018-05-04 | 2025-05-06 | Tagworks Pharmaceuticals B.V. | COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY |
-
2021
- 2021-05-05 AR ARP210101231A patent/AR122020A1/es unknown
- 2021-05-05 CN CN202180033900.4A patent/CN115551875A/zh active Pending
- 2021-05-05 EP EP21728368.8A patent/EP4146665A1/en active Pending
- 2021-05-05 TW TW110116294A patent/TW202207988A/zh unknown
- 2021-05-05 JP JP2022567076A patent/JP2023524288A/ja active Pending
- 2021-05-05 WO PCT/US2021/030905 patent/WO2021226247A1/en not_active Ceased
-
2022
- 2022-11-03 US US18/052,486 patent/US20230192760A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023524288A (ja) | 2023-06-09 |
| EP4146665A1 (en) | 2023-03-15 |
| TW202207988A (zh) | 2022-03-01 |
| US20230192760A1 (en) | 2023-06-22 |
| WO2021226247A1 (en) | 2021-11-11 |
| CN115551875A (zh) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122020A1 (es) | Sistemas y métodos para la conjugación específica de sitio de proteínas mediada por tirosinasa | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| MX2024013186A (es) | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo | |
| MA41287B1 (fr) | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| AR082630A1 (es) | Anticuerpos anti-tenascina-c a2 y metodos de uso | |
| EP2385955A4 (en) | MODIFIED ANTIBODY COMPOSITIONS, METHOD FOR THEIR PREPARATION AND USE | |
| PE20141162A1 (es) | Anticuerpos anti-il-23 | |
| CR9635A (es) | Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente | |
| CL2018000238A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| PE20060816A1 (es) | Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos | |
| DE69738166D1 (de) | Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren | |
| AR074321A1 (es) | Remocion de materiales objetivo utilizando metales de tierras raras | |
| MX2010005891A (es) | Analisis diferenciador. | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| MX2010008633A (es) | Ruptura de tolerancia inmunologica con un aminoacido no natural geneticamente codificado. | |
| CO5700783A2 (es) | Uso de b7-h3 como un agente inmuno regulatorio | |
| MX2018001686A (es) | Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco. | |
| PE20211497A1 (es) | Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso | |
| PE20231208A1 (es) | Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca | |
| BR112021016727A2 (pt) | Hidrolisados de proteína com rendimento aumentado de aminoácido n-terminal | |
| WO2022221827A3 (en) | Hyperactivators of mammalian dendritic cells | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo |